Replimune Group logo
Replimune Group REPL
$ 14.97 0.66%
report update icon

Quarterly report 2026-Q3
added 06-29-2026

Replimune Group Balance Sheet 2026-2011 | REPL

Brief overview of Replimune Group's balance sheet structure

The comparison uses five available annual reports from the 2021–2025 interval.

The asset base was stable: the change from $543.1 million to $551.3 million does not indicate a material increase in scale.

Liabilities grew faster than assets: +205.4% versus +1.5%. A substantial part of expansion was externally funded.

Internal capital represents 75.4% of the balance sheet, previously 91.8%. This is a strong capital position.

Cash exceeds interest-bearing debt, producing net debt of -$63.6 million. The balance sheet therefore carries a net cash position.

Cash represents 20.2% of assets versus 33.6% initially, showing how the immediate liquidity reserve changed.

Retained earnings remain negative at -$948.6 million. This may reflect past losses or substantial shareholder distributions, so earnings and buybacks provide important context.

Overall assessment

Taken together, the figures indicate acceptable resilience for Replimune Group. The next assessment depends on debt and equity trends.

Annual Balance Sheet Replimune Group

2026 2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Net Debt

-125 M -63.6 M -28.5 M -117 M - -157 M 59.4 M -19.1 M -17.6 M -20.6 M - - - - - -

Long Term Debt

83.3 M 46.4 M 44.8 M 28.6 M - 24.7 M 9.8 M - - - - - - - - -

Long Term Debt Current

1.16 M 1.18 M 1.16 M 1.12 M 1.07 M 970 K 873 K - - - - - - - - -

Total Non Current Liabilities

- - - - - - 38.5 M 6.58 M 52 K 32.3 M - - - - - -

Total Current Liabilities

58.2 M 62.4 M 40.4 M 33.8 M 20.8 M 14.5 M 11.9 M 9.88 M - - - - - - - -

Total Liabilities

166 M 135 M 113 M 91.3 M 50 M 44.4 M 50.4 M 16.5 M 5.22 M 34.3 M - - - - - -

Retained Earnings

-1.26 B -949 M -701 M -485 M -311 M -193 M -112 M -59.8 M -28.9 M -9.23 M - - - - - -

Total Assets

332 M 551 M 488 M 647 M 461 M 543 M 234 M 154 M 65.2 M 22.8 M - - - - - -

Cash and Cash Equivalents

209 M 111 M 74.5 M 147 M 106 M 183 M 59.5 M 25.7 M 17.7 M 20.7 M - - - - - -

Book Value

166 M 416 M 375 M 555 M 411 M 499 M 184 M 138 M 59.9 M -11.5 M - - - - - -

Total Shareholders Equity

166 M 416 M 375 M 555 M 411 M 499 M 184 M 138 M -28.1 M -11.5 M - - - - - -

All numbers in USD currency

Quarterly Balance Sheet Replimune Group

2026-Q3 2026-Q2 2026-Q1 2025-Q4 2025-Q3 2025-Q2 2025-Q1 2024-Q4 2024-Q3 2024-Q2 2024-Q1 2023-Q4 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Long Term Debt

47.6 M 47.2 M 46.8 M 47.6 M 47.2 M 46.8 M 46.4 M 46 M 45.6 M 45.2 M 44.8 M 44.4 M 29.2 M 28.9 M 28.6 M 28.4 M 24.2 M - 24.4 M 24.5 M 24.6 M 24.7 M 24.7 M 24.8 M 9.83 M 9.76 M 9.8 M 9.74 M 9.66 M 336 K 6.56 M 4.97 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Total Liabilities

123 M 126 M 133 M 123 M 126 M 133 M 135 M 121 M 117 M 109 M 113 M 111 M 97.2 M 89.9 M 91.3 M 83.2 M 52 M - 50 M 47.8 M 46.1 M 44.7 M 44.4 M 43 M 52.9 M 51.8 M 50.4 M 52.9 M 30.8 M 13.4 M 16.5 M 8.95 M 3.78 M 11.6 M 6.86 M - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Retained Earnings

-1.19 B -1.12 B -1.04 B -1.19 B -1.12 B -1.04 B -949 M -874 M -808 M -755 M -701 M -646 M -595 M -535 M -485 M -436 M -397 M - -311 M -280 M -250 M -220 M -193 M -172 M -150 M -130 M -112 M -96.5 M -80.3 M -69.2 M -59.8 M -53.1 M -45.4 M -39 M -28.9 M - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Total Assets

334 M 389 M 470 M 334 M 389 M 470 M 551 M 604 M 498 M 535 M 488 M 533 M 562 M 604 M 647 M 679 M 436 M - 461 M 485 M 503 M 524 M 543 M 559 M 314 M 330 M 234 M 250 M 151 M 144 M 154 M 152 M 154 M 59.3 M 65.2 M - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Cash and Cash Equivalents

123 M 102 M 97.4 M 123 M 102 M 97.4 M 111 M 174 M 115 M 153 M 74.5 M 99.3 M 77.6 M 108 M 147 M 208 M 90.6 M 114 M 106 M 134 M 162 M 193 M 183 M 324 M 43.3 M 105 M 59.5 M 63 M 53.3 M 38.4 M 25.7 M 21.1 M 23.3 M 12.9 M 17.6 M 39.2 M 67.7 M 16 M 20.7 M - - - 14.4 M - - - - - - - - - - - - - - - - - - - -

Book Value

211 M 263 M 337 M 211 M 263 M 337 M 416 M 482 M 381 M 426 M 375 M 422 M 465 M 514 M 555 M 595 M 384 M - 411 M 438 M 457 M 479 M 499 M 516 M 261 M 278 M 184 M 198 M 121 M 130 M 138 M 143 M 150 M 47.7 M 58.3 M - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Total Shareholders Equity

211 M 263 M 337 M 211 M 263 M 337 M 416 M 482 M 381 M 426 M 375 M 422 M 465 M 514 M 555 M 595 M 384 M 410 M 411 M 438 M 457 M 479 M 479 M 516 M 516 M 261 M 278 M 198 M 121 M 130 M 138 M 143 M 150 M 150 M -38.7 M - - - -11.5 M - - - - - - - - - - - - - - - - - - - - - - - -

All numbers in USD currency

Balance Sheet is a fundamental financial report of Replimune Group, providing a complete picture of the company’s financial position at a specific point in time. Unlike the income statement, which records the results of operations over a certain period, the balance sheet shows what assets the company owns, what liabilities it has to creditors, and what equity is available to the owners.

For an investor, the balance sheet is important because it allows assessing the company’s financial stability, understanding how much debt it carries, and how dependent it is on borrowed financing. It helps calculate key liquidity and leverage ratios. When analyzing, attention should be paid to the debt-to-equity ratio (Debt/Equity), the amount of cash on the balance sheet, and the ratio of current liabilities to liquid assets.

Features of balance sheet analysis
  • Vertical and horizontal analysis
    Vertical analysis shows the structure of the balance sheet as a percentage of total assets or liabilities, while horizontal analysis shows the dynamics of changes over multiple periods.
  • Asset quality
    It is important to evaluate not only the amount of assets but also their liquidity and realizability.
  • Accounting for off-balance sheet liabilities
    Some liabilities may not be directly reflected in the balance sheet, which requires additional attention.

Balance sheet of other industry stocks – Biotechnology

Issuer Price % 24h Market Cap Country
Celsion Corporation Celsion Corporation
CLSN
- -6.63 % $ 13.9 M usaUSA
FSD Pharma FSD Pharma
HUGE
- 5743.5 % $ 69.7 M canadaCanada
Qilian International Holding Group Limited Qilian International Holding Group Limited
QLI
- -6.08 % $ 184 M chinaChina
Happiness Biotech Group Limited Happiness Biotech Group Limited
HAPP
- 1.35 % $ 17.8 M chinaChina
Synthetic Biologics Synthetic Biologics
SYN
- 1.32 % $ 16.2 M usaUSA
Dynavax Technologies Corporation Dynavax Technologies Corporation
DVAX
- - $ 2.02 B usaUSA
BioXcel Therapeutics BioXcel Therapeutics
BTAI
$ 1.19 5.31 % $ 14.5 M usaUSA
Burford Capital Limited Burford Capital Limited
BUR
$ 4.37 0.23 % $ 958 M britainBritain
I-Mab I-Mab
IMAB
- - $ 866 M chinaChina
BeyondSpring BeyondSpring
BYSI
$ 0.84 34.27 % $ 34.5 M usaUSA
Corner Growth Acquisition Corp. Corner Growth Acquisition Corp.
COOL
- -0.89 % $ 114 M usaUSA
AgeX Therapeutics AgeX Therapeutics
AGE
- -10.17 % $ 12.2 K usaUSA
Alexion Pharmaceuticals, Inc. Alexion Pharmaceuticals, Inc.
ALXN
- - $ 40.3 B usaUSA
Genfit SA Genfit SA
GNFT
- 2.54 % $ 160 B franceFrance
Biophytis SA Biophytis SA
BPTS
- -13.47 % $ 169 M franceFrance
Cerus Corporation Cerus Corporation
CERS
$ 2.98 4.93 % $ 568 M usaUSA
Compugen Ltd. Compugen Ltd.
CGEN
$ 2.41 4.17 % $ 225 M israelIsrael
CureVac N.V. CureVac N.V.
CVAC
- - $ 867 M germanyGermany
EyeGate Pharmaceuticals, Inc. EyeGate Pharmaceuticals, Inc.
EYEG
- -1.52 % $ 24.7 M usaUSA
Athira Pharma Athira Pharma
ATHA
- - $ 269 M usaUSA
BiondVax Pharmaceuticals Ltd. BiondVax Pharmaceuticals Ltd.
BVXV
- 0.74 % $ 768 M israelIsrael
Abcam plc Abcam plc
ABCM
- - $ 4.9 B britainBritain
Завод ДИОД Завод ДИОД
DIOD
- - - russiaRussia
Galera Therapeutics Galera Therapeutics
GRTX
- -32.59 % $ 7.61 M usaUSA
Midatech Pharma plc Midatech Pharma plc
MTP
- -18.52 % $ 27.3 M britainBritain
Hepion Pharmaceuticals Hepion Pharmaceuticals
HEPA
- -18.79 % $ 39.3 K usaUSA
ARCA biopharma ARCA biopharma
ABIO
- 1052.0 % $ 415 M usaUSA
MorphoSys AG MorphoSys AG
MOR
- 2.43 % $ 254 M germanyGermany
Champions Oncology Champions Oncology
CSBR
$ 5.1 2.63 % $ 70.5 M usaUSA
Affimed N.V. Affimed N.V.
AFMD
- -34.95 % $ 21.5 M germanyGermany
AnPac Bio-Medical Science Co., Ltd. AnPac Bio-Medical Science Co., Ltd.
ANPC
- -1.58 % $ 28.1 M chinaChina
Celyad Oncology SA Celyad Oncology SA
CYAD
- - $ 12.5 M belgiumBelgium
Adial Pharmaceuticals Adial Pharmaceuticals
ADIL
$ 3.98 1.86 % $ 2.66 M usaUSA
Generation Bio Co. Generation Bio Co.
GBIO
- - $ 344 M usaUSA
Akero Therapeutics Akero Therapeutics
AKRO
- - $ 3.67 B usaUSA
AnaptysBio AnaptysBio
ANAB
$ 58.47 4.37 % $ 1.68 B usaUSA
Anika Therapeutics Anika Therapeutics
ANIK
$ 21.5 1.56 % $ 308 M usaUSA
Cyclacel Pharmaceuticals Cyclacel Pharmaceuticals
CYCCP
- -4.36 % $ 27 M usaUSA
Gracell Biotechnologies Gracell Biotechnologies
GRCL
- - $ 3.37 B chinaChina
Aurinia Pharmaceuticals Aurinia Pharmaceuticals
AUPH
$ 15.47 1.91 % $ 2.08 B canadaCanada
GlycoMimetics GlycoMimetics
GLYC
- 9357.83 % $ 1.01 B usaUSA
Aeterna Zentaris Aeterna Zentaris
AEZS
- 5.93 % $ 314 M canadaCanada
AVROBIO AVROBIO
AVRO
- 1083.1 % $ 745 M usaUSA
BeiGene, Ltd. BeiGene, Ltd.
BGNE
- 0.49 % $ 251 B cayman-islandsCayman-islands
Bicycle Therapeutics plc Bicycle Therapeutics plc
BCYC
$ 3.9 0.24 % $ 270 M britainBritain
Beam Therapeutics Beam Therapeutics
BEAM
$ 26.75 0.91 % $ 2.65 B usaUSA
AIkido Pharma AIkido Pharma
AIKI
- 1.93 % $ 17.4 M usaUSA
Aeglea BioTherapeutics Aeglea BioTherapeutics
AGLE
- - $ 1.01 B usaUSA
BioMarin Pharmaceutical BioMarin Pharmaceutical
BMRN
$ 67.36 0.99 % $ 12.9 B usaUSA
Aptose Biosciences Aptose Biosciences
APTO
- -45.71 % $ 1.2 M canadaCanada